Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Eisai Rufinamide Study Reports 33 Percent Reduction In Epileptic Seizures

Related Content

Eisai Epilepsy Drug Rufinamide Is "Approvable"

Sep 18 2006

Synosia Will Initiate Phase II Studies Of Rufinamide In Anxiety, Bipolar Disorders In March

Jan 25 2008

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window